Fig. 5: SLC26A3 expression in non-transformed cells and active disease.
From: Adaptation to inflammatory acidity through neutrophil-derived adenosine regulation of SLC26A3
a Brightfield images of respective colonoids following 6 and 24 h 100 μM Ado or 10 μM forskolin treatment. b The size of C57BL/6 derived intestinal colonoidss treated with 100 μM Ado or 10 μM forskolin were quantified by measuring the pixels/colonoid at 6 and 24 h (n = 3). c Induced SLC26A3 expression by 3 h 100 μM Ado treatment in mouse colonic colonoids via RT-PCR (n = 3). d Induced SLC26A3 and NR4A2 expression by 3 h 100 μM Ado treatment in human colonoids via RT-PCR (n = 3). e Representative confocal images depicting localization and expression of SLC26A3 (Green) and DAPI (Blue) in control, Crohn’s, active UC, and inactive UC colons. f Quantification of epithelial specific SLC26A3 expression via fluorescent intensity ratio between SLC26A3 and DAPI in control, Crohn’s, active UC, and inactive UC colons. Data expressed as both the average of each experiment (right) and individual values (left) (n = 4). n = number of independent experiments performed, separate passages of cells were used for each experiment. The data for each experiment was pooled and expressed as the mean ± SEM and p-value determined by ANOVA or T-test, *p < 0.01, **p < 0.001, **p < 0.0001.
